CD22-directed CAR-T cell therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CD22-directed CAR-T cell therapy, covering 2026-02-18 to 2026-02-18. Get the full timeline:
Most recent: Clinical Trial Update: A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma [Phase 1, Phase 2]